{"id":9040,"date":"2023-07-06T14:31:13","date_gmt":"2023-07-06T12:31:13","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=9040"},"modified":"2024-04-30T13:55:30","modified_gmt":"2024-04-30T11:55:30","slug":"an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/de\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/","title":{"rendered":"An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis"},"content":{"rendered":"
\n

Iago Rodr\u00edguez-Lago<\/a>\u00a01<\/a><\/sup>,\u00a0Leticia Abecia<\/a>\u00a02<\/a><\/sup>,\u00a0Iratxe Seoane<\/a>\u00a02<\/a><\/sup>,\u00a0Juan Anguita<\/a>\u00a03<\/a><\/sup>,\u00a0Jos\u00e9 Luis Cabriada<\/a>\u00a04<\/a><\/sup>Gastroenterol Hepatol.\u00a02023 Jul 6:S0210-5705(23)00370-9.\u00a0doi: 10.1016\/j.gastrohep.2023.07.001.[Article in English, Spanish]<\/p>\n<\/div>\n\n

\n

Objective: <\/strong>Primary non-response and secondary loss of response to anti-TNF agents are common in inflammatory bowel disease. Increasing drug concentrations are correlated to better clinical response and remission rates. Combination of granulocyte-monocyte apheresis (GMA) with anti-tumor necrosis factor (TNF) agents could be an option in these patients. The objective of our study was to perform an in vitro assay to determine if the GMA device can lead to infliximab (IFX) adsorption.<\/p>\n<\/div>\n\n

\n

Patients and methods: <\/strong>A blood sample was obtained from a healthy control. It was incubated with three concentrations of IFX (3, 6, and 9\u03bcg\/ml) at room temperature for 10min. At that time, 1ml was collected to determine the IFX concentration. Then, 10ml of each drug concentration was incubated with 5ml of cellulose acetate (CA) beads from the GMA device at 200rpm for 1h at 37\u00b0C to simulate physiological human conditions. A second sample of each concentration was collected and IFX levels were determined.<\/p>\n<\/div>\n\n

\n

Results: <\/strong>No statistically significant differences were observed in the IFX levels in the blood samples before and after incubation with the CA beads (p=0.41) and after repeated measurements (p=0.31). Mean change was 3.8\u03bcg\/ml.<\/p>\n<\/div>\n\n

\n

Conclusions:\u00a0<\/strong>The in vitro combination of GMA and IFX did not change the circulating levels of IFX at the three concentrations tested, suggesting that there is no interaction between the drug and the apheresis device in vitro and that they might be safely combined with each other.<\/p>\n<\/div>\n\n

\n

An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis – PubMed (nih.gov)<\/a><\/p>\n<\/div>\n\n

\n

An in vitro analysis of the interaction between infliximab and granulocyte\u2013monocyte apheresis – ScienceDirect<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Iago Rodr\u00edguez-Lago\u00a01,\u00a0Leticia Abecia\u00a02,\u00a0Iratxe Seoane\u00a02,\u00a0Juan Anguita\u00a03,\u00a0Jos\u00e9 Luis Cabriada\u00a04Gastroenterol Hepatol.\u00a02023 Jul 6:S0210-5705(23)00370-9.\u00a0doi: 10.1016\/j.gastrohep.2023.07.001.[Article in English, Spanish] Objective: Primary non-response and secondary loss of response to anti-TNF agents are common in inflammatory bowel disease. Increasing drug concentrations are correlated to better clinical response and remission rates. Combination of granulocyte-monocyte apheresis (GMA) with anti-tumor necrosis factor (TNF) agents could be […]<\/p>\n","protected":false},"template":"","scientific_tags":[103,303,750,424,109,749,435,748,306],"class_list":["post-9040","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-adsorption","scientific_tags-combination","scientific_tags-drug-levels","scientific_tags-gma","scientific_tags-infliximab","scientific_tags-interaction","scientific_tags-lor","scientific_tags-primary-non-response","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37422185\/<\/a>\r\n\r\nhttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S0210570523003709?via%3Dihub<\/a>"},"yoast_head":"\nAn in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Iago Rodr\u00edguez-Lago\u00a01,\u00a0Leticia Abecia\u00a02,\u00a0Iratxe Seoane\u00a02,\u00a0Juan Anguita\u00a03,\u00a0Jos\u00e9 Luis Cabriada\u00a04Gastroenterol Hepatol.\u00a02023 Jul 6:S0210-5705(23)00370-9.\u00a0doi: 10.1016\/j.gastrohep.2023.07.001.[Article in English, Spanish] Objective: Primary non-response and secondary loss of response to anti-TNF agents are common in inflammatory bowel disease. Increasing drug concentrations are correlated to better clinical response and remission rates. Combination of granulocyte-monocyte apheresis (GMA) with anti-tumor necrosis factor (TNF) agents could be […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-30T11:55:30+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/\",\"name\":\"An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2023-07-06T12:31:13+00:00\",\"dateModified\":\"2024-04-30T11:55:30+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/","og_locale":"de_DE","og_type":"article","og_title":"An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis - Adacyte","og_description":"Iago Rodr\u00edguez-Lago\u00a01,\u00a0Leticia Abecia\u00a02,\u00a0Iratxe Seoane\u00a02,\u00a0Juan Anguita\u00a03,\u00a0Jos\u00e9 Luis Cabriada\u00a04Gastroenterol Hepatol.\u00a02023 Jul 6:S0210-5705(23)00370-9.\u00a0doi: 10.1016\/j.gastrohep.2023.07.001.[Article in English, Spanish] Objective: Primary non-response and secondary loss of response to anti-TNF agents are common in inflammatory bowel disease. Increasing drug concentrations are correlated to better clinical response and remission rates. Combination of granulocyte-monocyte apheresis (GMA) with anti-tumor necrosis factor (TNF) agents could be […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/","og_site_name":"Adacyte","article_modified_time":"2024-04-30T11:55:30+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/","name":"An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2023-07-06T12:31:13+00:00","dateModified":"2024-04-30T11:55:30+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/an-in-vitro-analysis-of-the-interaction-between-infliximab-and-granulocyte-monocyte-apheresis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner\/9040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/media?parent=9040"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific_tags?post=9040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}